Home » Stocks » IGMS

IGM Biosciences, Inc. (IGMS)

Stock Price: $59.45 USD -0.25 (-0.41%)
Updated Apr 19, 2021 1:48 PM EDT - Market open
Market Cap 1.91B
Revenue (ttm) n/a
Net Income (ttm) -81.36M
Shares Out 30.75M
EPS (ttm) -26.20
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 19
Last Price $59.45
Previous Close $59.69
Change ($) -0.25
Change (%) -0.41%
Day's Open 58.65
Day's Range 58.00 - 60.71
Day's Volume 80,034
52-Week Range 41.41 - 133.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

STOCKHOLM, April 16, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) announced today that its Board of Directors appoints Magnus Christensen, the company's CFO, as interim CEO of Medivir. Magnu...

3 days ago - PRNewsWire

STOCKHOLM, April 6, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report for 2020 now is available at the company's website: www.medivir.com. In the spring of ...

1 week ago - PRNewsWire

STOCKHOLM, March 31, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the number of shares and votes in Medivir has changed during March 2021 as a result of the previously a...

2 weeks ago - PRNewsWire

– Recommended Phase 2 Dose for IGM-2323 Expected in 2021 –

2 weeks ago - GlobeNewsWire

STOCKHOLM, March 25, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announced that the last patient with advanced liver cancer has been included in the first part of the phase Ib study w...

3 weeks ago - PRNewsWire

MOUNTAIN VIEW, Calif., March 24, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today...

3 weeks ago - GlobeNewsWire

STOCKHOLM, March 22, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that Yilmaz Mahshid leaves the position as CEO of Medivir. The nomination committee proposes that he is elec...

3 weeks ago - PRNewsWire

HUDDINGE, Sweden, March 11, 2021 /PRNewswire/ -- Resolution on a directed issue of shares The extraordinary general meeting in Medivir Aktiebolag (publ) on 11 March 2021 resolved, in accordance with the...

1 month ago - PRNewsWire

STOCKHOLM, March 8, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the virtual meeting H.C. Wainwright Global Life Sciences Conference, March 9...

1 month ago - PRNewsWire

STOCKHOLM, Feb. 26, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the number of shares and votes in Medivir has changed during February 2021 as a result of the previously...

1 month ago - PRNewsWire

MOUNTAIN VIEW, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today ...

2 months ago - GlobeNewsWire

STOCKHOLM, Jan. 12, 2021 /PRNewswire/ -- Medivir AB (publ) (Nasdaq Stockholm: MVIR) today announced that it has entered into an exclusive licensing agreement, through which IGM Biosciences, Inc. (Nasdaq...

3 months ago - PRNewsWire

- IGM to Develop Birinapant in Combination with IGM-8444 for the Treatment of Solid Tumors - - IGM to Develop Birinapant in Combination with IGM-8444 for the Treatment of Solid Tumors -

3 months ago - GlobeNewsWire

MOUNTAIN VIEW, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today ...

3 months ago - GlobeNewsWire

Short squeezes don't typically live up to their expectations.

3 months ago - The Motley Fool

MOUNTAIN VIEW, Calif., Dec. 11, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) (IGM) today announced the closing of its upsized underwritten public offering of 1,221,224 shares of its com...

4 months ago - GlobeNewsWire

MOUNTAIN VIEW, Calif., Dec. 08, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) (IGM) today announced the pricing of its upsized underwritten public offering of shares of its common stock ...

4 months ago - GlobeNewsWire

MOUNTAIN VIEW, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) today announced that it intends to offer and sell $150 million of shares of its common stock and, in lieu of...

4 months ago - GlobeNewsWire

- 9 of 14 P atients S howed R eduction in T umor S ize, I ncluding T wo R ecently R eported C omplete R esponses -

4 months ago - GlobeNewsWire

MOUNTAIN VIEW, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today ...

4 months ago - GlobeNewsWire

MOUNTAIN VIEW, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today ...

4 months ago - GlobeNewsWire

MOUNTAIN VIEW, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today ...

5 months ago - GlobeNewsWire

MOUNTAIN VIEW, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- - Initial D ata from Phase 1 T rial of IGM-2323 in R elapsed/ r efractory N on-Hodgkin's L ymphoma to be Presented at the 62nd American Society o...

5 months ago - GlobeNewsWire

- Abstract Shows Encouraging Safety and Cytokine Release Data, Preservation of T cell Function and Repeatable T cell Activation - - Abstract Shows Encouraging Safety and Cytokine Release Data, Preservat...

5 months ago - GlobeNewsWire

MOUNTAIN VIEW, Calif., Sept. 30, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today...

6 months ago - GlobeNewsWire

- Multi-year, Multi-target Agreement Intended to Expedite Discovery of Novel IgM Antibodies - - Multi-year, Multi-target Agreement Intended to Expedite Discovery of Novel IgM Antibodies -

6 months ago - GlobeNewsWire

Analysts also positive on Charles River, Gilead and Horizon Therapeutics

6 months ago - GuruFocus

IGM Biosciences (IGMS) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

7 months ago - Zacks Investment Research

The firms that we cover on Wall Street increasingly are starting to agree that the volatility the stock market is encountering now, and the beating the economy has taken this year, should continue to fa...

Other stocks mentioned: CRL, GILD, HZNP
7 months ago - 24/7 Wall Street

  Insider buying can be an encouraging signal for potential investors when markets are near all-time highs.

Other stocks mentioned: KDP, XRX, CAR, GBDC, KOD
7 months ago - Benzinga

MOUNTAIN VIEW, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, tod...

7 months ago - GlobeNewsWire

­IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the second quarter e...

8 months ago - GlobeNewsWire

MOUNTAIN VIEW, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, toda...

8 months ago - GlobeNewsWire

- Companies to utilize proprietary platforms to discover, develop, and manufacture potential  therapeutic antibodies to combat ongoing COVID-19 pandemic -

11 months ago - GlobeNewsWire

Clinical trial successes could send shares of these drugmakers screaming higher.

Other stocks mentioned: BCYC, BTAI
11 months ago - The Motley Fool

IGM Biosciences, Inc. (IGMS) CEO Fred Schwarzer on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

After a solid 2019 has seen mixed trading in 2020, and after a massive run over the last decade, many investors are still trying to decide where and how they want their assets positioned in their portfo...

Other stocks mentioned: CDMO, ENDP, ILMN, ISEE, KOD, MYL, NVCN ...
1 year ago - 24/7 Wall Street

- Expert in the research and development of apoptotic pathways and antibody drug conjugates - - Expert in the research and development of apoptotic pathways and antibody drug conjugates -

1 year ago - GlobeNewsWire

Karuna Therapeutics, NextCure, and Cortexyme aren’t household names when it comes to investors looking at initial public offerings (IPOs), but they’ve been generating big-time returns for investors who ...

Other stocks mentioned: BYND, CRTX, INMD, KRTX, NXTC, PLMR, SWAV ...
1 year ago - ETF Trends

About IGMS

IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of multiple diseases. Its lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 1 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). The company is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers and NHL; and IGM-7354, is a bispecific IgM antibody delivering interleukin-15 cytokines to PD-L... [Read more...]

Industry
Biotechnology
IPO Date
Sep 18, 2019
Stock Exchange
NASDAQ
Ticker Symbol
IGMS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for IGMS stock is "Buy." The 12-month stock price forecast is 101.63, which is an increase of 70.96% from the latest price.

Price Target
$101.63
(70.96% upside)
Analyst Consensus: Buy